MRI Measures of Alzheimer's Disease and the AddNeuroMed Study

Andrew Simmons; Eric Westrnan; Sebastian Muehlboeck; Patrizia Mecocci; Bruno Vellas; Magda Tsolaki; Iwona Kloszewska; Lars-Olof Wahlund; Hilkka Soininen; Simon Lovestone; Alan Evans; Christian Spenger

doi:10.1111/j.1749-6632.2009.05063.x

MRI Measures of Alzheimer's Disease and the AddNeuroMed Study

Andrew Simmons, Eric Westrnan, Sebastian Muehlboeck, Patrizia Mecocci, Bruno Vellas, Magda Tsolaki, Iwona Kloszewska, Lars-Olof Wahlund, Hilkka Soininen, Simon Lovestone, Alan Evans, Christian Spenger

Research output: Chapter in Book/Report/Conference proceeding › Conference paper

118 Citations (Scopus)

Abstract

Here we describe the AddNeuroMed multicenter magnetic resonance imaging (MRI) study for longitudinal assessment in Alzheimer's disease (AD). The study is similar to a faux clinical trial and has been established to assess longitudinal MRI changes in AD, mild cognitive impairment (MCI), and healthy control subjects using an image acquisition protocol compatible with the Alzheimer's Disease Neuroimaging Initiative (ADNI). The approach consists of a harmonized MRI acquisition protocol across centers, rigorous quality control, a central data analysis hub, and an automated image analysis pipeline. Comprehensive quality control measures have been established throughout the study. An intelligent web-accessible database holds details on both the raw images and data processed using a sophisticated image analysis pipeline. A total of 378 subjects were recruited (130 AD, 131 MCI, 117 healthy controls) of which a high percentage (97.3%) of the T1-weighted volumes passed the quality control criteria. Measurements of normalized whole brain volume, whole brain cortical thickness, and point-by-point group-based cortical thickness measurements, demonstrating the power of the automated image analysis techniques employed, are reported.

Original language	English
Title of host publication	Biomarkers in Brain Disease
Place of Publication	OXFORD
Publisher	Blackwell Publishing
Pages	47 - 55
Number of pages	9
Volume	1180
ISBN (Print)	978-1-57331-772-6
DOIs	https://doi.org/10.1111/j.1749-6632.2009.05063.x
Publication status	Published - 2009
Event	Conference on Biomarkers in Brain Disease - Oxford, ENGLAND Duration: 26 Jan 2009 → 28 Jan 2009

Publication series

Name	BIOMARKERS IN BRAIN DISEASE

Conference

Conference	Conference on Biomarkers in Brain Disease
City	Oxford, ENGLAND
Period	26/01/2009 → 28/01/2009

Access to Document

10.1111/j.1749-6632.2009.05063.x

Cite this

Simmons, A., Westrnan, E., Muehlboeck, S., Mecocci, P., Vellas, B., Tsolaki, M., Kloszewska, I., Wahlund, L.-O., Soininen, H., Lovestone, S., Evans, A., & Spenger, C. (2009). MRI Measures of Alzheimer's Disease and the AddNeuroMed Study. In Biomarkers in Brain Disease (Vol. 1180, pp. 47 - 55). (BIOMARKERS IN BRAIN DISEASE). Blackwell Publishing. https://doi.org/10.1111/j.1749-6632.2009.05063.x

@inbook{9f73939689f249929f793696eb90be28,

title = "MRI Measures of Alzheimer's Disease and the AddNeuroMed Study",

abstract = "Here we describe the AddNeuroMed multicenter magnetic resonance imaging (MRI) study for longitudinal assessment in Alzheimer's disease (AD). The study is similar to a faux clinical trial and has been established to assess longitudinal MRI changes in AD, mild cognitive impairment (MCI), and healthy control subjects using an image acquisition protocol compatible with the Alzheimer's Disease Neuroimaging Initiative (ADNI). The approach consists of a harmonized MRI acquisition protocol across centers, rigorous quality control, a central data analysis hub, and an automated image analysis pipeline. Comprehensive quality control measures have been established throughout the study. An intelligent web-accessible database holds details on both the raw images and data processed using a sophisticated image analysis pipeline. A total of 378 subjects were recruited (130 AD, 131 MCI, 117 healthy controls) of which a high percentage (97.3%) of the T1-weighted volumes passed the quality control criteria. Measurements of normalized whole brain volume, whole brain cortical thickness, and point-by-point group-based cortical thickness measurements, demonstrating the power of the automated image analysis techniques employed, are reported.",

author = "Andrew Simmons and Eric Westrnan and Sebastian Muehlboeck and Patrizia Mecocci and Bruno Vellas and Magda Tsolaki and Iwona Kloszewska and Lars-Olof Wahlund and Hilkka Soininen and Simon Lovestone and Alan Evans and Christian Spenger",

year = "2009",

doi = "10.1111/j.1749-6632.2009.05063.x",

language = "English",

isbn = "978-1-57331-772-6",

volume = "1180",

series = "BIOMARKERS IN BRAIN DISEASE",

publisher = "Blackwell Publishing",

pages = "47 -- 55",

booktitle = "Biomarkers in Brain Disease",

note = "Conference on Biomarkers in Brain Disease ; Conference date: 26-01-2009 Through 28-01-2009",

}

Simmons, A, Westrnan, E, Muehlboeck, S, Mecocci, P, Vellas, B, Tsolaki, M, Kloszewska, I, Wahlund, L-O, Soininen, H, Lovestone, S, Evans, A & Spenger, C 2009, MRI Measures of Alzheimer's Disease and the AddNeuroMed Study. in Biomarkers in Brain Disease. vol. 1180, BIOMARKERS IN BRAIN DISEASE, Blackwell Publishing, OXFORD, pp. 47 - 55, Conference on Biomarkers in Brain Disease, Oxford, ENGLAND, 26/01/2009. https://doi.org/10.1111/j.1749-6632.2009.05063.x

TY - CHAP

T1 - MRI Measures of Alzheimer's Disease and the AddNeuroMed Study

AU - Simmons, Andrew

AU - Westrnan, Eric

AU - Muehlboeck, Sebastian

AU - Mecocci, Patrizia

AU - Vellas, Bruno

AU - Tsolaki, Magda

AU - Kloszewska, Iwona

AU - Wahlund, Lars-Olof

AU - Soininen, Hilkka

AU - Lovestone, Simon

AU - Evans, Alan

AU - Spenger, Christian

PY - 2009

Y1 - 2009

N2 - Here we describe the AddNeuroMed multicenter magnetic resonance imaging (MRI) study for longitudinal assessment in Alzheimer's disease (AD). The study is similar to a faux clinical trial and has been established to assess longitudinal MRI changes in AD, mild cognitive impairment (MCI), and healthy control subjects using an image acquisition protocol compatible with the Alzheimer's Disease Neuroimaging Initiative (ADNI). The approach consists of a harmonized MRI acquisition protocol across centers, rigorous quality control, a central data analysis hub, and an automated image analysis pipeline. Comprehensive quality control measures have been established throughout the study. An intelligent web-accessible database holds details on both the raw images and data processed using a sophisticated image analysis pipeline. A total of 378 subjects were recruited (130 AD, 131 MCI, 117 healthy controls) of which a high percentage (97.3%) of the T1-weighted volumes passed the quality control criteria. Measurements of normalized whole brain volume, whole brain cortical thickness, and point-by-point group-based cortical thickness measurements, demonstrating the power of the automated image analysis techniques employed, are reported.

AB - Here we describe the AddNeuroMed multicenter magnetic resonance imaging (MRI) study for longitudinal assessment in Alzheimer's disease (AD). The study is similar to a faux clinical trial and has been established to assess longitudinal MRI changes in AD, mild cognitive impairment (MCI), and healthy control subjects using an image acquisition protocol compatible with the Alzheimer's Disease Neuroimaging Initiative (ADNI). The approach consists of a harmonized MRI acquisition protocol across centers, rigorous quality control, a central data analysis hub, and an automated image analysis pipeline. Comprehensive quality control measures have been established throughout the study. An intelligent web-accessible database holds details on both the raw images and data processed using a sophisticated image analysis pipeline. A total of 378 subjects were recruited (130 AD, 131 MCI, 117 healthy controls) of which a high percentage (97.3%) of the T1-weighted volumes passed the quality control criteria. Measurements of normalized whole brain volume, whole brain cortical thickness, and point-by-point group-based cortical thickness measurements, demonstrating the power of the automated image analysis techniques employed, are reported.

UR - http://www.scopus.com/inward/record.url?scp=70449413764&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2009.05063.x

DO - 10.1111/j.1749-6632.2009.05063.x

M3 - Conference paper

SN - 978-1-57331-772-6

VL - 1180

T3 - BIOMARKERS IN BRAIN DISEASE

SP - 47

EP - 55

BT - Biomarkers in Brain Disease

PB - Blackwell Publishing

CY - OXFORD

T2 - Conference on Biomarkers in Brain Disease

Y2 - 26 January 2009 through 28 January 2009

ER -

MRI Measures of Alzheimer's Disease and the AddNeuroMed Study

Abstract

Publication series

Conference

Access to Document

Other files and links

Fingerprint

Cite this